Effect of metformin and L-carnitine in treatment of fatty liver

Comparison of the therapeutic effect of metformin and L-carnitine on ultrasound scoring and liver enzymes in patients with non-alcoholic fatty liver

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023083N3

Enrollment

Registered

2019-12-29

Start date

2019-08-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group:The first group received L-carnitine 1 g and VitE800 for 6 months. Intervention 2: Intervention group :the second group received metformin 1g and Vit E 800 for 6 mon

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range 18_65 years old Patients based on ultrasound evidence and testing of non-alcoholic fatty liver

Exclusion criteria

Exclusion criteria: People under the age of 18 Pregnant and lactating women People with kidney failure 30>GFR People with heart failure HF Class 3 and 4 People with liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Serum Spartate Aminotransferase Level. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Haleh Rezaee

Tabriz University of Medical Sciences

Rezaeeha@tbzmed.ac.ir+98 41 3337 2250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026